Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.46 |
| ▸ | PDE4A | P27815 | 7/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.46 |
| ▸ | NQO2 | P16083 | 4/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.46 |
| ▸ | CD38 | P28907 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12053148 | 0.90 | NQO2 (0.47) | PDE4BPDE4DPDE4APDE4CNQO2 | |
| SCHEMBL730520 | 0.90 | PDE4B (0.68) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL730861 | 0.84 | CYP19A1 (0.45) | PDE4BPDE4DNQO2CYP19A1 | |
| SCHEMBL12053147 | 0.83 | PDE4B (0.55) | PDE4BPDE4DPDE4APDE4CNQO2 | |
| SCHEMBL3676884 | 0.81 | PDE4B (0.81) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL730828 | 0.80 | NQO2 (0.49) | PDE4BNQO2CYP19A1 | |
| SCHEMBL729405 | 0.79 | NQO2 (0.44) | PDE4BPDE4DPDE4APDE4CNQO2 | |
| SCHEMBL730897 | 0.79 | NQO2 (0.46) | PDE4BNQO2CYP19A1 | |
| SCHEMBL723600 | 0.78 | PDE4B (0.47) | PDE4BNQO2CYP19A1 | |
| SCHEMBL730965 | 0.78 | CYP19A1 (0.45) | PDE4BNQO2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9078887-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078887-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9078887-B2 | Bicyclic heteroaryl inhibitors of PDE4 | KALYPSYS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20130178498-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178498-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178498-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130116279-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116279-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116279-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2013-02-21 | — | — | US | disclosed |
| WO-2011093924-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC (US) | 2011-08-04 | — | — | WO | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20100022586-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022586-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100022586-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20080027099-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027099-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027099-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | Govek, Steven (US) | 2008-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178498-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 9/4885PDE4A 1/4885 |
| US-20100022586-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 4/4885PDE4A 1/4885 |
| US-20130045975-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 9/4885PDE4A 1/4885 |
| US-20080027099-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 9/4885PDE4A 1/4885 |
| US-20130116279-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 9/4885PDE4A 1/4885 |
| US-20100081646-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 9/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.